The global API intermediate market is anticipated to grow at a significant CAGR of 7.6% during the forecast period. One of the major factors that are fuelling the market is the increase in cases of cardiovascular diseases such as heart attack, cardiomyopathy, deep vein thrombosis and pulmonary embolism, and others. The use of API intermediates is heavily being used in the treatment of these diseases. These cardiovascular diseases are a cause of major concern, being the leading cause of deaths globally arising out of noncommunicable diseases. Many major players in the industry are coming up with new product launches and acquisitions to propel the growth of the market. For instance, In July 2021, Glenmark Life Sciences launched its IPO in order to double its capacity over the next four years at a cumulative investment of over Rs 600 crore. Glenmark Life Science is a leading developer and manufacturer of select high value, non-commoditised APIs in chronic therapeutic areas, including cardiovascular disease, central nervous system disease, pain management and diabetes.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/api-intermediate-market
For instance, Novasep Holding SAS, a provider of services and technology to the life sciences industry, invested roughly $6.76 million USD in its France location to expand its capabilities in areas like oncology, the central nervous system (CNS), and infectious illnesses. This investment will help the company to develop new products and medications. Furthermore, in August 2021, Teva Pharmaceutical Inc. got approval from The United States Food and Drug Administration (FDA) on MED in Cell’s TV-46000/MDC-IRM, New Drug Application. The medication is being used to treat schizophrenia, a chronic and disabling mental disorder.
For instance, in August 2020, Pfizer Inc. announced a multi-year partnership with Gilead Sciences Inc. to produce and distribute Gilead’s investigational antiviral remdesivir, which will help the company scale up the supply of the COVID-19 therapy.
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
o By Product
o By Type of Intermediate
o By Therapeutic Application
- Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape – Pfizer, Inc., Sanofi S.A., Novartis International AG, Lupin Pharmaceuticals, Inc., and BASF SE among others
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Global API Intermediate Market Report Segment
By Product
- Chemical Intermediates
- Biotech Intermediates
By Type of Intermediates
- Patent Intermediates
- Non-Patent Intermediates
By Therapeutic Application
- Oncology
- Diabetes
- Cardiovascular Disease
- CNS & Neurological Disorders
- Endocrinology
- Others
A full report of API intermediate Market is available at: https://www.omrglobal.com/industry-reports/api-intermediate-market
API intermediate Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- Hipharma Ltd.
- Jigs Chemical Ltd
- Pfizer Inc.
- Novartis International AG
- Teva Pharmaceutical Industries Ltd.
- Merck & Co., Inc.
- Dragon Hwa ChemPharm. Co., Ltd.
- Shandong Jiulong Fine Chemical Co., Ltd.
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
